Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema

International Ophthalmology

Volumn 38, Issue 1, 2018, Pages 293-299

  Chen, Yen Yi ^a   Chen, Pei Ying ^a,b   Chen, Fang Ting ^a,c   Chen, Yun Ju ^a,c   Wang, Jia Kang ^a,c,d,e,f  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e YUAN ZE UNIVERSITY   (Taiwan)

^f ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

Author keywords

Diabetic macular edema; Intravitreal injection; Ranibizumab; Vitrectomized eyes

Indexed keywords

CHOLESTEROL; CREATININE; GLYCOSYLATED HEMOGLOBIN; RANIBIZUMAB; ANGIOGENESIS INHIBITOR;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL FOVEAL THICKNESS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC MACULAR EDEMA; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PSEUDOPHAKIA; RETROSPECTIVE STUDY; VISUAL SYSTEM PARAMETERS; VITRECTOMY; DIABETES MELLITUS; DOSE RESPONSE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PROCEDURES; RETINA MACULA LUTEA; TIME FACTOR; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 85011880012     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-017-0462-1     Document Type: Article

References (17)

1. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611
2. Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, Eguchi S, Hori S (2005) Vitreous levels of vascular endothelial growth factor and intracellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112:806–816
3. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ, RIDE and RISE Research Group (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022
4. Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P, RESTORE Extension Study Group (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121:1045–1053
5. Bressler SB, Glassman AR, Almukhtar T, Bressler NM, Ferris FL, Googe JM Jr, Gupta SK, Jampol LM, Melia M, Wells JA, Diabetic Retinopathy Clinical Research Network (DRCR.net) (2016) Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol 164:57–68
6. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130:972–979
7. Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M (2012) Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci 53:5877–5880
8. Chin HS, Park TS, Moon YS, Oh JH (2005) Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25:556–560
9. Christoforidis JB, Williams MM, Wang J, Jiang A, Pratt C, Abdel-Rasoul M, Hinkle GH, Knopp MV (2013) Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina 33:946–952
10. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M (2003) Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681–686
11. Ahn SJ, Ahn J, Park S, Kim H, Hwang DJ, Park JH, Park JY, Chung JY, Park KH, Woo SJ (2014) Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci 55:567–573
12. Ahn J, Kim H, Woo SJ, Park JH, Park S, Hwang DJ, Park KH (2013) Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther 29:612–618
13. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF (2007) Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 144:124–126
14. Kondo M, Ito Y, Terasaki H (2007) Intravitreal bevacizumab (Avastin) for treatment of persistent macular edema in vitrectomized eyes: limited effect and early recurrence. Retina Cases Brief Rep 1:195–197
15. Okamoto Y, Okamoto F, Hiraoka T, Oshika T (2014) Vision-related quality of life and visual function following intravitreal bevacizumab injection for persistent diabetic macular edema after vitrectomy. Jpn J Ophthalmol 58:369–374
16. Bressler SB, Melia M, Glassman AR, Almukhtar T, Jampol LM, Shami M, Berger BB, Bressler NM, Diabetic Retinopathy Clinical Research Network (2015) Ranibizumab plus prompt or deferred laser for diabetic macular edema eyes with vitrectomy before anti-vascular endothelial growth factor therapy. Retina 35:2516–2528
17. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103:1796–1806